Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6DG6

Structure of a de novo designed Interleukin-2/Interleukin-15 mimetic

Summary for 6DG6
Entry DOI10.2210/pdb6dg6/pdb
DescriptorNeoleukin-2/15 (2 entities in total)
Functional Keywordscytokine mimetic, biosynthetic protein
Biological sourcesynthetic construct
Total number of polymer chains6
Total formula weight72677.03
Authors
Jude, K.M.,Silva, D.-A.,Yu, S.,Baker, D.,Garcia, K.C. (deposition date: 2018-05-16, release date: 2019-01-16, Last modification date: 2024-04-03)
Primary citationSilva, D.A.,Yu, S.,Ulge, U.Y.,Spangler, J.B.,Jude, K.M.,Labao-Almeida, C.,Ali, L.R.,Quijano-Rubio, A.,Ruterbusch, M.,Leung, I.,Biary, T.,Crowley, S.J.,Marcos, E.,Walkey, C.D.,Weitzner, B.D.,Pardo-Avila, F.,Castellanos, J.,Carter, L.,Stewart, L.,Riddell, S.R.,Pepper, M.,Bernardes, G.J.L.,Dougan, M.,Garcia, K.C.,Baker, D.
De novo design of potent and selective mimics of IL-2 and IL-15.
Nature, 565:186-191, 2019
Cited by
PubMed Abstract: We describe a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but are otherwise unrelated in topology or amino acid sequence. We use this strategy to design mimics of the central immune cytokine interleukin-2 (IL-2) that bind to the IL-2 receptor βγ heterodimer (IL-2Rβγ) but have no binding site for IL-2Rα (also called CD25) or IL-15Rα (also known as CD215). The designs are hyper-stable, bind human and mouse IL-2Rβγ with higher affinity than the natural cytokines, and elicit downstream cell signalling independently of IL-2Rα and IL-15Rα. Crystal structures of the optimized design neoleukin-2/15 (Neo-2/15), both alone and in complex with IL-2Rβγ, are very similar to the designed model. Neo-2/15 has superior therapeutic activity to IL-2 in mouse models of melanoma and colon cancer, with reduced toxicity and undetectable immunogenicity. Our strategy for building hyper-stable de novo mimetics could be applied generally to signalling proteins, enabling the creation of superior therapeutic candidates.
PubMed: 30626941
DOI: 10.1038/s41586-018-0830-7
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.999 Å)
Structure validation

227111

건을2024-11-06부터공개중

PDB statisticsPDBj update infoContact PDBjnumon